Agomelatine for treatment of Obsessive-Compulsive Disorder

Agomelatine as Adjunctive Therapy in Obsessive Compulsive Disorder A Double-blind,Placebo-controlled,Randomized Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170123032145N5

Enrollment

Registered

2020-07-14

Start date

2020-09-22

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: Sertraline(Tab) up to 200 mg/day plus Agomelatine (Tab) 25 mg daily for 12 weeks. Intervention 2: Control group: Sertraline(Tab) up to 200 mg/day plus placebo(Tab)

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients who meet DSM-5 criterion for OCD Achieve more than 21 for Yale-Brown Obsessive Compulsive Scale Age: 18-65 year old Sign consent form

Exclusion criteria

Exclusion criteria: They should not be treated by any psychiatric intervention for last 6 weeks. If they show any other important mental condition or suicidal thought, neurological deficit, will exclude from study. They will be evaluated for cardiac, liver, kidney, pregnancy, lactation and mental retardation before entrance and any mentioned conditions will cause exclusion from study.

Design outcomes

Primary

Measure	Time frame
Severity of obsessive-compulsive disorder. Timepoint: Weeks: 0, 4, 8 and 12. Method of measurement: Yale-Brown Obsessive Compulsive Scale(YBOCS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammadreza Shalbafan

Iran University of Medical Sciences

shalbafa.mr@iums.ac.ir+98 21 6655 1665

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 10, 2026